Sponsored By:

4 Pharmaceutical Stocks to Buy Now

RPRX, JNJ, BMY, WPI improve in weekly rankings

   

Four Pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, Repros Therapeutics (NASDAQ:RPRX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.

The rating of Johnson & Johnson (NYSE:JNJ) moves up this week, rising from a B to an A. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.

Bristol-Myers Squibb (NYSE:BMY) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.

Watson Pharmaceuticals (NYSE:WPI) earns an A this week, jumping up from last week’s grade of B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/03/4-pharmaceutical-stocks-to-buy-now-rprx-jnj-bmy/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.